Aveo drops on delay for Phase III tivozanib readout

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) fell $0.69 (24%) to $2.16 on Tuesday after delaying for at least

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE